HN2301
/ Shenzhen MagicRNA Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 14, 2026
Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)
(clinicaltrials.gov)
- P=N/A | N=30 | Recruiting | Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Trial completion date: Mar 2026 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026
Trial completion date • Trial primary completion date • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis
February 13, 2026
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
(clinicaltrials.gov)
- P=N/A | N=9 | Terminated | Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd | Trial completion date: Dec 2026 ➔ Feb 2026 | Initiation date: Jun 2025 ➔ Jan 2026 | Recruiting ➔ Terminated | Trial primary completion date: May 2026 ➔ Feb 2026; Change of registrant
Trial completion date • Trial initiation date • Trial primary completion date • Trial termination • CNS Disorders • Myasthenia Gravis
1 to 2
Of
2
Go to page
1